Jason Fung: What Happened to “Statins Save Lives”?
Jason Fung, Physician, Nephrologist, shared a post on X about a recent article by Jes S Lindholt et al., published in European Heart Journal, adding:
“What happened to ‘statins save lives’?
In this 31,000 person RCT over 7 years, CVD screening put 44.33% of people on statins (compared to 30.25% in non screening) but prevented neither deaths nor CV events (HR 0.96).
Funny how I don’t see this trial ever being discussed by cardiologists. One major difference with this trial compared to so many other statin trials is that it is not funded by a statin maker.”
Title: Outcomes of cardiovascular screening in men aged 60–64 years: the DANCAVAS II trial
Authors: Jes S Lindholt, Anne Mejldal, Lars M. Rasmussen, Jess Lambrechtsen, Flemming H. Steffensen, Lars Frost, Kenneth Egstrup, Grazina Urbonaviciene, Martin Busk, Marek Karon, Axel Cosmus Pyndt Diederichsen
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 12, 2026, 17:55Dries De Wolf: Honored to Have Wolfgang Miesbach Comment on Our Latest Research
-
Sep 12, 2026, 17:53Usman Waheed: Introducing the Discovery of the 49th ISBT Blood Group System
-
Sep 12, 2026, 17:51Maria Sabater Lleal: Happy to Share Our Latest Work Exploring the Genetic Determinants of PE in VTE
-
Sep 12, 2026, 17:51Jeff Sternlicht: Why LDL-C and ApoB Remain King of the Hill?
-
Sep 12, 2026, 17:49Kalyan Roy: TRAGS – An Emerging Transfusion Safety Concern
-
Sep 12, 2026, 17:47Eric Topol: Most Supplements and Vitamins Offer Little Proven Benefit
-
Sep 12, 2026, 17:44Manuel Monreal: Clinical Characteristics, Treatment, and Outcomes in Hispanic vs Caucasian Patients With VTE
-
Sep 12, 2026, 17:43Sidi Mohamed El Amine Benlazar: CPX-351 and Ruxolitinib in Advanced-Phase Myeloproliferative Neoplasms
-
Sep 12, 2026, 17:42Elad Asher: Higher IPF Is Associated with Adverse Outcomes in ICCU